Market revenue in 2023 | USD 442.9 million |
Market revenue in 2030 | USD 791.7 million |
Growth rate | 8.7% (CAGR from 2023 to 2030) |
Largest segment | Regulatory writing & publishing |
Fastest growing segment | Legal Representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
Key market players worldwide | Genpact Ltd, Icon PLC, Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Drug Development, Cencora Inc, Pharmexon, QVigilance, Voisin Consulting Life Sciences, Accell, Criterium Inc., Freyr Solutions, PharmaLex, NDA Regulatory Service GmbH, BlueReg Group, Cambridge Regulatory Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 31.52% in 2023. Horizon Databook has segmented the Japan biopharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is the second largest pharmaceutical market, followed by the U.S. The well-established pharmaceutical industry in Japan is the major factor driving the pharmaceutical regulatory affairs market.
The country is expected to dominate the pharmaceutical regulatory affairs market during the forecast period in Asia Pacific due to the rising demand for new and cost-effective medicines, which may attract investments from biopharmaceutical companies.
Rising demand for generics due to government support and improvement in regulatory approval processes are expected to increase the number of market entrants, propelling the demand for regulatory services.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biopharmaceutical regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into Japan biopharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account